Is Mounjaro Available in the UK?

How NICE and the MHRA confirmed tirzepatide's place in the UK

The MHRA granted Mounjaro its UK marketing authorisation for weight management in November 2023, following the clinical trial programme that demonstrated results not previously seen with a single licensed weight-loss medicine. NICE followed with its appraisal, TA1026, published in December 2024, formally recommending tirzepatide on the NHS for adults with a BMI of 35 or above plus at least one weight-related comorbidity. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

The evidence base underpinning those decisions is substantial. In the SURMOUNT-1 trial, adults taking the 15 mg dose achieved an average body-weight reduction of around 20–21% over 72 weeks, making tirzepatide the most effective medicine currently licensed for weight management in the UK. The trial enrolled 2,539 participants, so these are not small-study signals. In the SURMOUNT-5 head-to-head study, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same period. Both bodies of evidence informed the MHRA and NICE decisions that tirzepatide is indeed available, appropriate and effective for use in the UK.

Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA continues to collect additional safety data, as it does for all newer medicines. That is standard practice, not a restriction on access.

NHS access versus private prescription: where things stand right now

NICE approval does not mean instant NHS availability for everyone who qualifies. The NHS is rolling out access in defined phases. From June 2025, patients with a BMI of 40 or above and four or more of the five qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes) became eligible. A second cohort (BMI 35–39.9 with four or more conditions) was activated in June 2026. Further expansion is planned. GP practices can prescribe under the updated GP contract from April 2026, though participation is optional, so what is available on the NHS varies considerably by area and practice. Every NHS patient is also required to engage with wraparound diet and activity support. For the detailed NHS rollout timetable and eligibility criteria, the NHS England weight management injections guidance is the authoritative source.

Private prescription bypasses the waiting list entirely. There is no referral needed and no phase to wait for. A GPhC-registered Independent Prescriber assesses your consultation the same day it is submitted. If Mounjaro is clinically suitable, treatment is dispatched the same day (for orders placed before midday, Monday to Friday) and delivered free the next working day. If you are wondering about the cost side of private treatment, the Mounjaro pricing page sets out what a private prescription typically involves and what is included.

Is tirzepatide available in any other form in the UK?

At present, the only licensed form of tirzepatide available in the UK is the once-weekly subcutaneous injection, supplied as a pre-filled KwikPen by Eli Lilly. Each pen contains four weekly doses at a single strength. Treatment starts at 2.5 mg (a tolerability-focused starting point) and is titrated upward by the prescriber through 5, 7.5, 10, 12.5 and 15 mg as the treatment progresses.

An oral form of tirzepatide is in development, and it attracts understandable curiosity given that the oral route removes the injection entirely. If you have already been looking into this, the pages on whether oral tirzepatide is available and when an oral version might arrive in the UK cover the current regulatory position. The short answer: no oral tirzepatide product has received UK approval at the time of writing, and if you are curious whether Mounjaro is available in tablet form, that page explains the current position in full. For comparison, oral semaglutide (Wegovy tablets) received MHRA approval for weight management in June 2026, that is a different drug on the same principle, and it is worth reading about the weight-loss treatment options available now if you are weighing injection versus tablet.

Storage for the injection pen is straightforward: keep it refrigerated at 2–8°C. For the precise room-temperature window and other handling details, the Mounjaro Patient Information Leaflet is the definitive reference, your prescriber will confirm this at the time of treatment.

What the consultation process looks like

Because Mounjaro is a prescription-only medicine, access through any legitimate route requires a clinical assessment. At nume, that process is entirely online. You complete a consultation, which is read and reviewed the same day by a GPhC-registered Independent Prescriber. There is no automated decision-making. The prescriber checks your BMI, health history, any medicines you take and any contraindications before deciding whether to prescribe.

Worth knowing: orders placed before midday tend to be the most straightforward to dispatch the same day, so if you are planning around a busy week (a holiday coming up, a Monday start) it is worth factoring that in. The service runs Monday to Friday. Aftercare is available seven days a week. There are no subscriptions and no auto-renewals; every repeat order is clinically re-reviewed before dispatch, and if you are ever concerned that you have accidentally taken too much Mounjaro, that page sets out what to do and when to seek help.

You can learn more about the team behind the clinical decisions on the clinical team page, or browse the FAQs if you have a specific question before starting. When you are ready, check your eligibility with a free consultation.